Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Effect of SCN5A depletion on gene expression in xenograft tumours of MDA-MB-231 breast cancer cells

ABSTRACT: Effect of SCN5A depletion on gene expression in xenograft tumours of MDA-MB-231 breast cancer cells

PROVIDER: PRJNA950459 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR24030133_1.fastq.gz	Fastqsanger.gz
	SRR24030133_2.fastq.gz	Fastqsanger.gz
	SRR24030134_1.fastq.gz	Fastqsanger.gz
	SRR24030134_2.fastq.gz	Fastqsanger.gz
	SRR24030135_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 24

Similar Datasets

Effect of SCN5A depletion on gene expression in xenograft tumours of MDA-MB-231 breast cancer cells

Project description:To investigate the function of SCN5A in tumour progression, we previously established an MDA-MB-231 cell line in which the target gene has been stably knocked down using lentiviral shRNA. The cell line (or equivalent cells expressing control shRNA) was orthotopically implanted into the 4th inguinal mammary fat pad of 6-week old immunodeficient Rag2−/− Il2rg−/− female mice and tumours allowed to form. We then performed gene expression profiling analysis using data obtained from RNA-seq of 6 tumours derived from control and shRNA SCN5A cell lines.

2024-09-27 | GSE228621 | GEO

Epigenome analysis of MTHFD2 as a biomarker for decitabine response in MDA-MB-231 tumours

Project description:Genome-wide DNA methylation profiling of MDA-MB-231 tumours with or without MTHFD2 knockdown and decitabine treatment. The Illimuna Infinium MethylationEPIC DNA Beadchip v-1-0 B3 was used to obtain DNA methylation performed by The Centre for Applied Genomics in Toronto, Canada.

2024-11-01 | GSE267582 | GEO

Effect of ectopic expression of sFRP1 on MDA-MB-231 human breast cancer cells in vitro and in vivo as xenograft

Project description:RNA was isolated from ectopically sFRP1-expressing MDA-MB-231 cells and control MDA-MB-231 cells and as well from tumor lysates arising from these cells as nude mouse xenograft. Gene expression profiles for these samples were investigated using Affymetrix arrays.

2009-05-01 | GSE13806 | GEO

The miRNA profiling in MDA-MB-231, MDA-MB-231/E1A and knockdown of Dicer in MDA-MB-231/E1A cells

Project description:Dicer, RNase III endonuclease, is an essential enzyme in miRNA biogenesis that regulates target gene expression, and it has been reported that aberrant expressions of Dicer associate with the clinical outcomes of patients in various cancers. To explore the miRNA differencial expression regulated by Dicer in MDA-MB-231/E1A cells, the microarray profiling analysis was employed to conduct differentially expressed miRNAs in stable MDA-MB-231/vector, MDA-MB-231/E1A, and MDA-MB-231/E1A/shDicer cells.

2016-01-16 | GSE76924 | GEO

Expression data from MDA-MB-231 parental and xenograft tumor cells treated with Smac mimetic SM-164.

Project description:Small-molecule Smac mimetics target inhibitor of apoptosis (IAP) proteins to induce TNFÎ±-dependent apoptosis in cancer cells and several Smac mimetics have been advanced into clinical development as a new class of anticancer drugs. However, preclinical studies have shown that only a small subset of cancer cell lines are sensitive to Smac mimetics used as single agents and these cell lines are at risk of developing drug resistance to Smac mimetics. Thus, it is important to understand the molecular mechanisms underlying intrinsic and acquired resistance of cancer cells to Smac mimetics in order to develop effective therapeutic strategies to overcome or prevent Smac mimetic resistance. We established Smac mimetic resistant sublines derived from MDA-MB-231 breast cancer cells, which exhibit exquisite sensitivity to the Smac mimetic SM-164, and used microarrays to detail the global programme of gene expression underlying SM-164 resistance in MDA-MB-231 cells and identified differentially expressed genes in SM-164-resistant and -sensitive MDA-MB-231 cells. SCID mice with MDA-MB-231 xenograft tumors were treated with 5 mg/kg of SM-164 intravenously for 5 days/week for 2 weeks. SM-164-regressed MDA-MB-231 tumors regrew after treatment ended. Tumor cells from these regrown MDA-MB-231 tumors were isolated and total RNAs were prepared for microarray analysis.

2012-03-01 | E-GEOD-33827 | biostudies-arrayexpress

The miRNA profiling in MDA-MB-231, MDA-MB-231/E1A and knockdown of Dicer in MDA-MB-231/E1A cells

2016-01-16 | E-GEOD-76924 | biostudies-arrayexpress

Expression profiles of MDA-MB-231, MDA-231 S1a and S1b

Project description:Identification of genes that are involved in self-seeding by comparing gene expression profiles between parental MDA-MB-231 cells and seeder cells (MDA-231-S1a and S1b) 2 replicates from each sample (parental MDA-MB-231, MDA-MB-231 S1a and MDA-MB-231 S1b) were analyzed

2010-04-07 | E-GEOD-18833 | biostudies-arrayexpress

Gene expression profile of breast cancer cell line MDA-MB-231 xenograft

Project description:Gene expression profile of breast cancer cell line MDA-MB-231 xenograft

| PRJNA780574 | ENA

Expression profiles of MDA-MB-231, MDA-231 S1a and S1b

Project description:Identification of genes that are involved in self-seeding by comparing gene expression profiles between parental MDA-MB-231 cells and seeder cells (MDA-231-S1a and S1b)

2010-03-25 | GSE18833 | GEO

Gene expression profile of breast cancer cell line MDA-MB-231 xenograft - discovery set

Project description:Progression to stage IV disease remains the main cause of breast cancer-related deaths. Increasing knowledge of the hematogenous phase of metastasis is key for exploiting the entire window of opportunity to interfere with early dissemination and to achieve a more effective disease control. On the hypothesis that the distinguishing molecular features of circulating tumor cells (CTCs) reveal useful information on metastasis biology and disease outcome, we compared the transcriptomes of CTCs and solid primary/secondary lesions of the MDA-MB-231 xenograft model and provided evidence that blood-borne dissemination is regulated by numerous genes. Our new CTC-specific signature improved CTC detection and outcome prognostication in early-stage breast cancer patients compared to conventional CTC markers, and shed light on the metastatic process by highlighting the role of two genes.

2022-03-02 | GSE188893 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data